You are here

Targeting distinct DNA methylation signatures in pediatric glioma using HITMA

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 75N91022C00007
Agency Tracking Number: 75N91022C00007
Amount: $355,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCICA22
Solicitation Number: 75N91020R00043
Timeline
Solicitation Year: 2021
Award Year: 2022
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
3439 NE SANDY BLVD. #330
PORTLAND, OR 97232-1959
United States
DUNS: 078667905
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 MICHAEL ROUNTREE
 (720) 883-2041
 mike.rountree@nzumbeinc.com
Business Contact
 JAMES STAFFORD
Phone: (503) 201-6797
Email: james.stafford@nzumbeinc.com
Research Institution
N/A
Abstract

Pediatric high-grade gliomas (pHGG) have proven to be extremely difficult to treat with a dismal survival rate. Fresh, innovative therapeutic approaches are desperately needed to combat this devastating disease. Hypomethylated Induced Target Mediated Apoptosis (HITMA), is a therapeutic strategy that targets and induces apoptosis only in cells that show an aberrant DNA methylation phenotype at repetitive sequences. Aberrant global DNA methylation is a hallmark of some pHGGs; however, the methylation status of repetitive sequences hasn’t been carefully evaluated. The first goal of this proposal is to thoroughly evaluate the methylation status of repetitive elements in different pHGG subtypes. Based on this, the second goal is to identify and generate an optimal HITMA strategy that will attack select subclasses of pHGG while sparing normal neural cell types. Therefore, if our HITMA-based strategy in pHGG is successful, we expect it to transform patient-specific therapeutic strategies in pHGG.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government